Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. - Wikidata - awgldk - TriplyDB

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

http://www.wikidata.org/entity/Q39427414

about

Nuclear receptors and AMPK: can exercise mimetics cure diabetes?Fibroblast Growth Factor Signaling in Metabolic Regulation Inventing new medicines: The FGF21 story Stressed Liver and Muscle Call on Adipocytes with FGF21 FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues.FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss.The Fibroblast Growth Factor signaling pathway Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms.Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein.Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.RNAi screening in primary human hepatocytes of genes implicated in genome-wide association studies for roles in type 2 diabetes identifies roles for CAMK1D and CDKAL1, among others, in hepatic glucose regulation.Receptor antibodies as novel therapeutics for diabetes.Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice Obesity surgery: happy with less or eternally hungry?Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21 Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis.Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification.The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling.MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity FGF21 mimetic shows therapeutic promise.FGF19 action in the brain induces insulin-independent glucose lowering Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: A (1)H NMR-based metabolomics investigation.Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans.Tanycytes As Regulators of Seasonal Cycles in Neuroendocrine Function.Nuclear receptors and metabolism: from feast to famine.Cooperation between brain and islet in glucose homeostasis and diabetes.An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities.Dual actions of fibroblast growth factor 19 on lipid metabolism.Effect of mitochondrial stress on systemic metabolism.FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.

P2860

Q26750875-C32FC148-CD36-473D-A61E-F83E812056CE Q26772751-77FB97E8-8142-4806-9F93-FA02AC38051F Q26823319-575E4F5B-4113-4E15-BF74-B391F29A239B Q27014973-8B0C9426-C20C-4ECC-A6BD-B049D6DCDB64 Q27028013-E8497A32-03B6-4CD7-8019-75E6547AA4CD Q27680518-D7B27FCB-39D0-44D8-9928-A7DB8DD7BEDD Q27686803-CC7C45C0-8070-4FEE-9E41-AF3C24B688A4 Q28244332-5B18153A-BCF7-4BF0-9D67-AE5DDCF0A701 Q33685319-60E26833-CF36-45F8-B054-BB8B42F9DC35 Q33726498-61AFC05B-0EFA-470A-954D-BFA41023A16B Q33869232-8592A6AD-C41D-4F35-B642-F683BBF0B715 Q34315567-3A757A33-C159-42B3-9A8A-541EA80C1B72 Q34467171-AD099F6C-48AB-41F6-8C0F-9043868A07EC Q34575896-D262A38A-6A55-4299-8A60-9677D8F6B376 Q34603360-FD80E314-D740-44C9-8FE1-F48C92FFD55B Q34695496-25819E24-0FCE-40A4-A2F5-51AD4A5AE8DE Q34778879-AD12EF20-C387-4DF8-90B3-852ACF611324 Q34804320-8A3951A8-3AD4-4EF1-8C78-92DCCF533F00 Q35218087-0A882653-C2E6-4964-890E-5AF5CA89A8DF Q35947503-D732AA72-DD92-4C67-9539-6B480F70A88D Q36248720-607DE603-1E94-4120-B4CD-5F5FCC9537D4 Q36261228-B0EF9431-7E54-422B-A58B-19E93CFF27F9 Q36589260-B35A196F-BA3F-4DAE-9CEB-C8DB354F6B35 Q36674741-ACD86264-FAA0-4B2E-BCB5-37A36BE666D0 Q36746670-6A26233F-1064-458C-B0C8-E528FF70D719 Q36746883-4D2A42E2-B452-4406-9487-8044ACD0495E Q36898306-F112C374-0961-4C4E-95CE-A1836B21C09E Q37160100-A5A70D09-C49C-48AA-BBFF-507D43ECB94A Q37211913-FBFBF136-3043-4354-9A43-133751BD6793 Q37259301-34FB888C-049A-4BB5-9DE2-64ABDA8A16F4 Q37390264-9C970FC1-1244-4543-B817-9E332BC49B44 Q37554768-D352C285-DA9E-4A62-90F0-78ABCC06D527 Q37691998-117FF57A-FF66-4B1B-8E3F-093A0F212D23 Q37692841-86465507-A17F-4895-AED1-4156845BEB34 Q37698362-AE990EF9-790A-4E65-8A91-E24D6AA432ED Q38290536-85266052-2D89-4054-A8CE-D462C0DA6875 Q38319578-937C4AB6-2666-4037-B242-2B77ABB01A1B Q38534812-E45E13C8-CF40-403B-8074-1A5A23849887 Q38744561-56E8549E-03C1-4B57-AB3C-DE7954BFD6A4 Q38794405-A27C01E5-6AE2-4189-A46F-073A739AD688

P2860

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

http://www.wikidata.org/entity/Q39427414

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@en

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@nl

type

label

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@en

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@nl

prefLabel

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@en

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@nl

P1433

Q39427414-2A5275AA-9121-4347-A04C-5EE42C0C1C93

P1476

Q39427414-582C772C-FDE0-4B9D-8C5D-63729EA52BBA

P2093

Q39427414-03FDBB09-CC17-45CD-BA97-3768BB7EDA15

Q39427414-0F5FFAD3-AC1D-44D3-BBAB-79E1188C1E90

Q39427414-0FC0145E-CD84-4240-9300-797FF228DEB8

Q39427414-1098CB79-DB41-49BE-8F8E-1D9C9F462C86

Q39427414-1DD3BBCA-3BBB-4C05-911E-73D529CE3896

Q39427414-31498EAD-5D4A-49F7-A178-E9808AAFECB8

Q39427414-38182AF8-8E5B-4E48-9FB5-6CB2E447BEAB

Q39427414-3DC51A72-8C49-4DC0-BED2-D1586ACAC030

Q39427414-4C0A1A31-2B3E-4C58-BECA-873BE7E3EE22

Q39427414-52EDE2F5-EA9F-4ED2-B020-77A8E441AFE4

P2860

Q39427414-02F4E27A-69BF-482D-9131-7BC17F457A7D

Q39427414-095FCDD3-1C9D-4050-9F48-80D0A60F3291

Q39427414-0BA1B32D-5380-4AD2-B930-052EF50BE838

Q39427414-24AD513F-E05C-43D8-A856-6218451D7379

Q39427414-3D5B824D-1B35-432E-811C-DFF1441B1398

Q39427414-43E6E6CC-FB66-48BF-820D-2FC262199076

Q39427414-45F34049-D9CE-4BB2-AE7E-2232F4EE1E48

Q39427414-4921E048-0A92-43D4-A936-37A770BFD77A

Q39427414-49B7FB25-B931-4F9D-BC89-BDA93D917A35

Q39427414-4A6A752C-2822-432E-8941-D5D2C9420B10

P304

Q39427414-C5E85E90-7599-4D19-9ED8-B9F63D4BE4BE

P31

Q39427414-44D37791-A35D-4B58-9BEF-B9D41F9EC9B5

P356

Q39427414-1E4BEB0B-5B9D-4BB4-A506-8B0586278086

P407

Q39427414-A748C72E-48AE-4084-888F-1A77F132BF81

P433

Q39427414-A104C1EC-5AED-41B3-9947-8CD178F27292

P478

Q39427414-3038C095-0C50-445B-9823-6814909C9751

P577

Q39427414-D7CBC6F4-9AE0-44E2-8CBB-E9101BC870F0

P698

Q39427414-854B35D1-AB06-45DE-8379-53C21295CB69

P921

Q39427414-40F2B440-D8B5-4BC9-B245-4B3C1F36BBA8

Q39427414-B530A2A2-7FB5-48C9-A97B-8C10DF972D12

P356

SCITRANSLMED.3002669

P1433

Science Translational Medicine

P1476

Amelioration of type 2 diabete ...... last growth factor receptor 1.

@en

P2093

Ai-Luen Wu

http://www.w3.org/2001/XMLSchema#string

Andrew S Peterson

http://www.w3.org/2001/XMLSchema#string

Anne Wong

http://www.w3.org/2001/XMLSchema#string

Bo Feng

http://www.w3.org/2001/XMLSchema#string

Daniel Yansura

http://www.w3.org/2001/XMLSchema#string

David West

http://www.w3.org/2001/XMLSchema#string

Elizabeth Luis

http://www.w3.org/2001/XMLSchema#string

Ellen Filvaroff

http://www.w3.org/2001/XMLSchema#string

Ganesh Kolumam

http://www.w3.org/2001/XMLSchema#string

Hok Seon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for FGF receptor dimerization and activation

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

FGF-21 as a novel metabolic regulator.

Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway

The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis

FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

P304

113ra126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3002669

http://www.w3.org/2001/XMLSchema#string

P407

P433

113

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22174314

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes